Floatz logo

Cyclophosphamide

Thymus Neoplasms

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Thymus Neoplasms cohort.

Asset / SponsorPhaseRating
Ribociclib
M.D. Anderson Cancer Center
Phase 2B
18f-flt
National Cancer Institute (NCI)
Phase 2CCC
Tnhyp217 Car T Cells
National Cancer Institute (NCI)
Phase 1CC
Fludarabine
National Cancer Institute (NCI)
Phase 1CC
Mithramycin
National Cancer Institute (NCI)
Phase 1/2D
Octreotide Pamoate
Federico II University
Phase 2NR

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →